Concepedia

Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

Ursula Schmidt‐Erfurth, Bora Eldem, Robyn H. Guymer, Jean‐François Korobelnik, Reinier O. Schlingemann, Ruth Axer‐Siegel, Peter Wiedemann, Christian Simader, Margarita Gekkieva, Andreas Weichselberger

Ophthalmology · 2010 · 388 citations · 11 references

DOI

Concepts

References

11

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text

, , +12

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

, , +13

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

David M. Brown, Mark Michels, Peter K. Kaiser et al. · Ophthalmology · 2008 · 1.3K citations

, , +15

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Carl D. Regillo, David M. Brown, Prema Abraham et al. · American Journal of Ophthalmology · 2008 · 862 citations

, , +10

The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency

Bruce A. Keyt, Lea T. Berleau, Hung Van Nguyen et al. · Journal of Biological Chemistry · 1996 · 605 citations · Full text

, , +10